PT  - JOURNAL ARTICLE
ED - BMJ Publishing Group Ltd
TI  - ▼ Apremilast for psoriasis and psoriatic arthritis
AID  - 10.1136/dtb.2015.9.0352
DP  - 2015 Sep 01
TA  - Drug and Therapeutics Bulletin
PG  - 105--108
VI  - 53
IP  - 9
4099  - http://dtb.bmj.com/content/53/9/105.short
4100  - http://dtb.bmj.com/content/53/9/105.full
SO  - Drug Ther Bull2015 Sep 01; 53
AB  - ▼ Apremilast (Otezla - Celgene Europe Ltd.) is a novel orally administered immunomodulatory medicine licensed for the treatment of plaque psoriasis and psoriatic arthritis.1 The company suggests that it has demonstrated proven and durable efficacy in both conditions and has a favourable safety profile with no requirement for drug-specific pre-screening or ongoing laboratory monitoring.i Here we review the evidence on the safety and efficacy of apremilast in the management of psoriasis and psoriatic arthritis.